Eastward Capital Partners provided the venture debt financing.
The company intends to use the funds to continue to enhance its product portfolio.
Originally founded as a spin-off from technology developed at MIT in 1985 and led by Gary S. Gillheeney, Sr., President and Chief Executive Officer, Organogenesis offers a portfolio of bioactive and acellular biomaterials products for advanced wound care, orthopedics, and spine.
FinSMEs
22/05/2017